# Nuclide record ga68-dotatate-then-lutathera (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/ga68-dotatate-then-lutathera/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "ga68-dotatate-then-lutathera" ;
  schema:name "68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)"@en ;
  schema:description "Before starting the neuroendocrine tumour treatment Lutathera, patients get a somatostatin-receptor PET scan to confirm the tumour actually has the right target for the drug to lock onto. Lutathera's approval and use are built around this scan-first rule."@en ;
  schema:url <https://nuclide.cc/pairings/ga68-dotatate-then-lutathera/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf>, <https://tech.snmjournals.org/content/jnmt/early/2022/06/14/jnmt.122.263813.full.pdf>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9737149/> ;
  nuclide:tag "neuroendocrine tumours", "theranostics", "patient selection" ;
  nuclide:related <https://nuclide.cc/targets/sstr2/>, <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/pairings/sstr-pet-to-prrt/>, <https://nuclide.cc/people/richard-baum/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/in-111/>, <https://nuclide.cc/isotopes/cu-64/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:pairs <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/lutathera/> .